TITLE:
A Study to Access the Safety/Efficacy of Thalidomide in the Treatment of Anemia in Patients With Myelodysplastic Syndromes

CONDITION:
Myelodysplastic Syndromes

INTERVENTION:
thalidomide

SUMMARY:

      The primary objective of the study is to determine the efficacy of thalidomide for the
      treatment of anemia in patients with myelodysplastic syndromes (MDS).
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to 80 Years
Criteria:

        -  Eligible patients must have a diagnosis of myelodysplastic syndrome

          -  Life expectancy of at least 6 months.

          -  Patients must be able to adhere to the study visit schedule and other protocol
             requirements.

          -  Patients must understand and voluntarily sign an informed consent document.

          -  Women of childbearing potential (WCBP) must agree to practice abstinence or to use
             TWO methods of contraception beginning 4 weeks prior to the start of study medication
             and throughout the course of treatment.

          -  Males must use barrier contraception when engaging in reproductive sexual activity
             with women of childbearing potential.
      
